About
Christian W. Mandl, Ph.D., M.D., is a Senior Advisor to Adjuvant Capital who consults for industry and non-profit organizations on vaccine and viral vector programs. He previously served as Senior Vice President of Research at VIR Biotechnology and, until 2015, as Global Head of Research, Early and Exploratory Clinical Development at Novartis Vaccines, where he initiated the self-amplifying RNA (SAM) technology. Before joining Novartis in 2008 he was Professor and Assistant Head of the Clinical Institute of Virology at the Medical University of Vienna, focusing on the molecular biology of RNA viruses and flaviviruses; he holds a PhD and MD from the University of Vienna and an MS in Biochemistry from Pennsylvania State University.
Invests in
Biotech
Experience
- Tiba BiotechChief Medical Officercurrent2025 — present
- Tiba BiotechChief Scientific Officer, Co-founder2018 — 2025Cambridge, MA, USA
- International Vaccine Institute (IVI)Member Board of Trusteescurrent2024 — presentSeoul, South Korea; Vienna, Austria
- International Vaccine Institute (IVI)Chair, Scientific Advisory Group (SAG)2018 — 2024Seoul, South Korea
- Vaccines and Viral VectorsConsultantcurrent2015 — presentLexington, MA, USA
- Adjuvant CapitalSenior Advisorcurrent2019 — presentNew York City Metropolitan Area
- AccuriusCo-Founder, Chief Scientific Officer2022 — 2026Lexington, MA, USA
- Themis Bioscience GmbHChair, Scientific Advisory Board2016 — 2020Vienna, Austria
- Vir Biotechnology, Inc.Senior Vice President, RNA Technologies2017Boston, MA
- Novartis VaccinesGlobal Head of Research, Early and Exploratory Clinical Development2014 — 2015Cambridge, MA, USA, and Siena, Italy
- Novartis VaccinesVice President, Clinical Franchise Head, Early and Exploratory Clinical Development2013 — 2014Cambridge, MA, USA
- Novartis VaccinesVice President, Head Vaccines Research US, Global Head Virus Research2008 — 2013Cambridge, MA, USA
- Medical University of ViennaDeputy Head of the Department of Virology2004 — 2008Vienna, Austria
- University of ViennaAssociate Professor of Virology1998 — 2003Vienna, Austria
Skills & more
IND1Vaccines81Virology38Biotechnology48Clinical Development39Clinical Trials27Clinical Research23Life Sciences30Molecular Biology19Infectious Diseases22Immunology19Biopharmaceuticals12
+12 more
Drug DiscoveryCell CultureDrug DevelopmentBiochemistryOncologyTechnology TransferCell BiologyProtein ChemistryLifesciencesPharmaceutical IndustryRegulatory AffairsGMPLanguages English · German
From Christian's professional profile.
Colleagues at Adjuvant Capital
Abrar Haque
Associate at Adjuvant Capital
Alexandra (Sandra) Glucksmann
Advisory Partner at Adjuvant Capital
Curt LaBelle
Venture Partner at Adjuvant Capital
Evelyn Yanatos
Director of Finance and Compliance at Adjuvant Capital
Gerard Cunningham
Operating Partner at Adjuvant Capital
Giulia Balconi
Associate at Adjuvant Capital
Glenn Rockman
Co-Founder and Partner at Adjuvant Capital
Jim Robinson
Senior Advisor at Adjuvant Capital
Frequently asked questions
- Who is Christian Mandl?
- Christian W. Mandl, Ph.D., M.D., is a Senior Advisor to Adjuvant Capital who consults for industry and non-profit organizations on vaccine and viral vector programs. He previously served as Senior Vice President of Research at VIR Biotechnology and, until 2015, as Global Head of Research, Early and Exploratory Clinical Development at Novartis Vaccines, where he initiated the self-amplifying RNA (SAM) technology. Before joining Novartis in 2008 he was Professor and Assistant Head of the Clinical Institute of Virology at the Medical University of Vienna, focusing on the molecular biology of RNA viruses and flaviviruses; he holds a PhD and MD from the University of Vienna and an MS in Biochemistry from Pennsylvania State University.
- Where does Christian Mandl work?
- Christian Mandl is Senior Advisor at Adjuvant Capital.
- What does Christian Mandl invest in?
- Christian Mandl invests in Biotech.
- Where did Christian Mandl go to school?
- Christian Mandl studied at University of Vienna (Doctor of Medicine (M.D.), Medicine); Austria (Medical Specialist, Virology); University of Vienna (Ph.D., Biochemistry).
Same school
Also attended University of Vienna45
Dominik MatykaInvestor at Cavalry VenturesAnnakaFinance at Maven VenturesKristina ChvilovaInvestor at Aglae VenturesManuela FürstAssociate Partner at Venionaire CapitalAlexander RapatzAssociate Partner - Munich and Luxembourg at Venionaire CapitalAstrid WoollardAssociate Partner at Venionaire Capital
+ 39 more
Also attended Penn State University189
Kelly DonovanExecutive Assistant & Operations Associate, Revolution Growth at RevolutionFallon GoodeExecutive Assistant at March Capital PartnersCristina HohlmanPartner, Chief Financial Officer at Sapphire VenturesNick DolikInvestor at 8VCRobert SoffelRevOps Expert at Notion CapitalLouis BernemanFounding Partner at Osage University Partners
.jpg)
.jpg)
+ 183 more
Shared employers
Also worked at Vir Biotechnology, Inc.3
Also worked at Novartis Vaccines130
Rebecca JamesInvestor at Index VenturesScott BillerInvestor at GV (Google Ventures)Freya Svedberg-KeatingInvestor at MedicxiAndrea AmadorCompliance Manager at Inveready Technology Investment GroupAbbie CelnikerInvestor at Third Rock VenturesJesper GromadaInvestor at Third Rock Ventures
+ 124 more
